TGFB1 and non-small cell lung carcinoma: To validate TGF-β1 as a potential serum biomarker for pre-clinical cardiovascular injury monitoring in NSCLC patients, we determined the cutoff point of serum TGF-β1 levels and validated TGF-β1 using ROC curves for NSCLC patients (the cutoff point was 1016.158 pg/mL, while the AUC value was 0.616).